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Abstract
With increased interest in clinical pro-
teomics—the comparative investigation of dif-
ferential protein expression patterns for use in
the diagnostic and prognostic assessment of
disease states—the demand for techniques that
can readily identify changes in select proteome
components is greater than ever before. This
article describes a targeted proteomics approach
to recover and quantify C-reactive protein
(CRP) directly from human plasma. CRP, a
putative biomarker for cardiac health, was
isolated from microliter volumes of human
plasma by using novel proteomics tools that
combine micro-scale affinity capture with matrix
assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS)
detection. Native CRP was analyzed along with
serum amyloid P component (SAP) and retinol
binding protein (RBP), that were intentionally
targeted to generate a selected protein expres-
sion profile. A number of qualitative changes
were readily observed within these profiles,
including micro heterogeneity in the SAP
glycan, C-terminally truncated versions of RBP,
and detection of a novel truncated variant of
CRP. After quantitative validation of increasing
plasma CRP concentrations, the approach was
applied to the analysis of eight plasma samples
obtained from individuals with known medical
histories. The result of the analyses are eight
protein profiles, revealing increasing CRP levels
that can be associated with individuals ailing
from post-surgery inflammation, chronic rheu-
matoid arthritis, and recent acute myocardial
infarction. The technique described in this arti-
cle lays the foundation for selected protein pro-
filing for use in biomarker discovery, as well as
in clinical and diagnostic applications. 
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Introduction
Clinical proteomics focuses on the use of
rapid fractionation approaches in combination
with mass spectrometry (MS) to directly profile
human biofluids, plasma in particular. By
design, these studies are meant to establish
protein signatures, in the form of mass spec-
tra, that are able to distinguish between
healthy and diseased states in individuals.
Indeed, numerous pioneering investigations
have shown clinical proteomics to be one of the
most promising new approaches for defining
diagnostic signatures related to ovarian, breast,
prostate and lung cancers (1–3). However, a
particular concern of these studies is that many
of the profiling approaches distinguish healthy
from diseased states based on computer learn-
ing algorithms that may not identify a land-
mark mass-to-charge (m/z) value as actually
being a protein species. Such an approach may
be misleading if the m/z values used have no
corresponding peptide signals. Moreover, to
date no clinical proteomics study has indepen-
dently “rediscovered” known biomarkers of
various cancers (e.g., prostate specific antigen
[PSA] is not detected in individuals suffering
from prostate cancer). In missing, or not specif-
ically targeting these proteins as part of the pro-
filing, these studies do not take full advantage
of past clinical/diagnostic studies, the results
of which are the basis of numerous current
diagnostic assays (4). Accordingly, there exists a
growing demand to discover and identify pro-
teins for use as putative biomarkers, and at the
same time detect proteins that are presently
used (and validated) as diagnostic species (5).
Given that the identity of the biomarker is
known (either old or newly found), it is
clearly more efficient to construct assays that
target them directly, rather than to continue to
assay samples using the global discovery
methodologies. A foremost advantage to using
a targeted approach in combination with mass
spectrometry is the ability to significantly
improve the limit of detection of the assay.
Specifically, affinity approaches are able to
selectively concentrate target proteins prior
to mass spectrometry, the result of which is
a highly purified form of the target protein
entering the mass spectrometer without any
accompanying interferences stemming from the
presence of other proteins (e.g., ion suppression
or overlapping signals). A second advantage is
the use of targeted high-performance mass
spectrometric assays to discern and character-
ize genomic and epigenomic differences that
are found in proteins. Because of genetic and
posttranslational variations, any protein under
investigation has the potential of existing within
or between individuals as multiple species.
Mass spectrometry of highly purified pro-
teins has been used for many years to both
detect and characterize and/or identify these
variations (6). This long-standing ability is ide-
ally complimented by a simple fractionation
approach that can be used to selectively con-
centrate chosen proteins directly from biologi-
cal milieu. 
Thus, findings made through efforts in
the fields of clinical biology and medicine,
including proteomics, stand to be improved
upon by: (1) knowing the identity of the
signature/biomarker proteins, (2) reducing the
signature profile to its essential components,
and (3) detecting structural and quantitative
variations—present in natural populations—
encountered in the proteins. Moreover, pro-
teomics technologies responsive to these needs
must be readily applied in the analysis of
hundreds-to-thousands of samples. 
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Overview of the Mass Spectrometric
Immunoassay Process
Previous works have described a hybrid
protein analysis technology—mass spectromet-
ric immunoassay (MSIA)—that is used to selec-
tively retrieve target proteins from complex
biological milieu for mass spectrometric
characterization and quantification (7–10).
Figure 1 gives a brief overview of the process.
As applied here, a human plasma sample is
repeatedly drawn and expelled through a
pipettor tip containing a stationary phase to
which an affinity ligand is covalently bound
(termed MSIA-Tip). After rinsing, MALDI
matrix is drawn into the MSIA-Tip, breaking
the affinity interaction. The resulting matrix/
analyte mixture is deposited directly onto a
mass spectrometer target for subsequent matrix-
assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS).
Analyte detection/characterization is essen-
tially a combination of affinity isolation via
immobilized antibodies and characterization
of retained species by MALDI-TOF MS. In
this sense, target proteins and their variants
are selectively concentrated from plasma, and
MALDI-TOF MS is used to (1) unambiguously
identify the wild-type target protein by detec-
tion at a known molecular weight and (2) rec-
ognize the presence of variants retained by the
antibody at masses shifted away from the wild-
type protein. This ability forms the basis of an
assay capable of identifying protein variants
resulting from posttranslational modifications
(9), pointmutations (10), or truncations (11–13).
The simultaneous analysis of mass-resolved
species lays the foundation for the rigorous
quantification of a target protein (14) or the
development of multiple-analyte assays (7). 
Presented here is the development of a
multi-analyte MSIA for use in the expres-
sion profiling of a select group of proteins—
C-reactive proteins (CRP), retinol binding pro-
tein (RBP), and serum amyloid P component
(SAP) (and their variants)—present in human
plasma. The central target in these analyses is
CRP, a known clinical protein biomarker of
inflammation that has been determined to
have short- and long-term predictive value of
patient outcomes with cardiovascular disease
and the development of coronary events that
can be used to identify the onset and recur-
rence of myocardial infarction (MI) (15–18),
stroke (19–20), and angina (21–22). The two
other protein species, RBP and SAP were
chosen as complement proteins (for use in
normalizing the MSIA profiles between indi-
viduals) based on a few simple criteria. First,
for optimization of MALDI-TOF MS condi-
tions (e.g., matrix, delayed-extraction), the
proteins must have similar, but fully resolved
molecular weights. Second, the complement
proteins are found in healthy populations at
roughly equivalent and reasonably stable con-
centrations. Lastly, MSIA conditions for the
complement proteins (e.g., extraction and
rinses) are the same as for the target protein.
Materials and Methods
Samples
Plasma samples from eight individuals (five
males and three females betweent the ages of
26 and 48) were acquired following a procedure
approved by the IBI’s Institutional Review
Board (IRB), and only after each subject
had signed an Informed Consent form. Sam-
ples were acquired, under sterile conditions,
through a lancet-punctured finger using two
nonheparinized (75 µL volume) microcolumns
(Drummond Scientific Co., Broomall, PA). Each
150 µL whole blood sample collected was
immediately combined with 200 µL HEPES
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buffered saline (10 mM HEPES, 150 mM NaCl,
pH 7.4 [HBS]) containing 50 mM ethylenedi-
amine tetraacetic acid (EDTA) and 2 µL of a
protease inhibitor cocktail set II (Calbiochem,
San Diego, CA), and centrifuged for 2 min (at
7000 rpm/2500g) to pellet red blood cells. The
supernatant (diluted plasma, 250 µL) was
decanted from each sample and stored at
–70°C until ready for use.
For the standard addition quantification
experiments, a single plasma sample was dis-
persed into eight 25 µL aliquots. Increasing
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Fig. 1. Schematic of the MSIA process. Biological fluid is passed through the MSIA-Tip and targeted analytes are
affinity bound within the solid support. Nonaffinity reactive components of the biological fluid are removed
from the MSIA-Tip with repetitive rinses. Purified target analyte is then eluted from the tip onto a MALDI
target for subsequent TOF MS analysis.
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amounts (0 through 7 aliquots of 14 µL) of
0.0183 mg/mL standard solution containing
highly purified human C-reactive protein (Cal-
biochem, San Diego, CA) were added to the
plasma aliquots. Each aliquot was then
brought to 300 µL with HBS-EDTA buffer. 
MSIA Analysis
The plasma samples were addressed in par-
allel using a multi channel pipettor, using CDI
(1,1’-carbonyldiimidazole)-activated MSIA-Tips
prepared and derivatized with polyclonal anti-
bodies specific towards retinol binding protein,
C-reactive protein and serum amyloid P com-
ponent (DakoCytomation, Carpinteria, CA), as
previously described (8). Sample incubation
consisted of 50 cycles (aspiration and dispens-
ing) of 150 µL of the sample through each
MSIA-Tip. After incubation, the MSIA-Tips were
thoroughly rinsed using HBS, 10 cycles of 150 µL;
double distilled water, 5 cycles of 150 µL; 20%
acetoniltrile/2M ammonium acetate, 10 cycles
of 150 µL; and finally with double distilled
water, 15 cycles of 150 µL. Retained proteins
were eluted by drawing 4 µL of MALDI matrix
solution (saturated aqueous solution of sinapic
acid (SA), in 33% (v/v) acetonitrile, 0.4% (v/v)
trifluoroacetic acid) into each tip and depositing
the eluates directly onto a 96-well formatted
hydrophobic/hydrophilic contrasting MALDI-
TOF target (14). Samples were allowed to air
dry prior to insertion of the MALDI target into
the mass spectrometer. The total time required
for preparation of the samples was less than
10 min.
MALDI-TOF MS
Intact protein expression profiling was
performed on a Bruker Biflex III MALDI-
TOF mass spectrometer operating in linear
delayed-extraction mode with 25.50 kV full
accelerating potential. Draw-out pulses of
2.175 kV (900 ns delay) were used for parent
protein analysis. Mass spectra were manually
acquired. Five spectra from each spot were
acquired and averaged for relative quantita-
tive measurements.
Results
Individual and Multi-Protein MSIA Assays
Assays for the individual proteins were
developed and investigated to gauge compati-
bility and to check for any unforeseen interfer-
ences. Figure 2 shows a comparison between
the MSIA analyses of human plasma for CRP,
RBP, SAP, and a MALDI-TOF MS analysis of
the stock plasma (diluted 100-fold with water,
taken prior to any MSIA extraction). In each
case, the target species was selectively isolated
to the exclusion of higher concentration plasma
proteins that are generally observed in the anal-
ysis of human plasma with no prior fractiona-
tion (i.e., albumin, apolipoproteins) (Fig. 2D).
Additionally, there is no signal overlap between
the chosen proteins (i.e., the three proteins reg-
ister at distinct m/z regions in the mass spectra),
nor are any interferences observed in the spec-
tra, owing to, for example, nonspecific binding. 
Based on the compatibility of the individ-
ual analyses, a multi-analyte MSIA was con-
structed by linking antibodies targeting the
three species to the same MSIA-Tip. Figure 3
shows the results of using the assay on a
plasma sample taken from a healthy 29-yr-old
male (Individual No. 5). Observed in the
profile are, from low-to-high mass: RBP-L
(C-terminally truncated RBP missing one
leucine residue, m/zobs = 20,951; m/zcalc = 20,953);
RBP (m/zobs = 21,065; m/zcalc = 21,066); CRP-P
(CRP missing its C-terminal proline residue,
m/zobs = 22,930; m/zcalc = 22,932); CRP (m/zobs
=23,028; m/zcalc = 23,029); SAP-V&sialic acid
(SAP missing one sialic acid and its C-terminal
valine, m/zobs = 25,068; m/zcalc = 25,073); SAP-
sialic acid (m/zobs = 25,168; m/zcalc = 25,172);
SAP-V (m/zobs = 25,359; m/zcalc = 25,364); and
SAP (m/zobs = 25,461; m/zcalc = 25,463). This sig-
nature (of eight species) was commonly
observed in repeated analyses of the Individ-
Protein Profiling in Human Plasma ____________________________________________________________ 11
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
ual No. 5 plasma, as well as in the subsequent
application of the assay to the all eight plasma
samples screened throughout the remainder of
the study.
Validation of CRP Response
As the foremost purpose of the assay was
that of viewing modulation in CRP, a standard
addition approach was used to confirm a
direct relationship between CRP signal inten-
sity and concentration. Eight samples (using
the Individual No. 5 sample) were prepared to
contain increasing amounts of CRP standard.
Figure 4 shows four (of the eight) CRP-MSIA
profiles performed on the standard addition
samples. The spectra are normalized to the
SAP signal height. When the ratio of the
CRP/SAP signal intensities for each aliquot
were plotted against the CRP concentration,
linear relationship (correlation r 2 = 0.984) is
observed in the concentration range of 0.0 to
6.0 mg/L (Fig. 5), thus verifying that an ele-
vated CRP response denotes an increase in
concentration. The endogenous concentration
of CRP in the individual was determined to be
0.069 mg/L from the line equation derived
from the data:
ICRP/ISAP = 0.463|[CRP]| + 0.319
This value is consistent with literature
values of basal CRP levels in healthy individ-
uals at < 1 mg/L (23).
Profiling Relative to Medical History 
Plasma samples from eight individuals—
with knowledge of their medical disposition—
were screened using the RBP–CRP–SAP assay.
Profiles comparable in detail to that shown in
Figure 3 were obtained for each individual.
Figure 6 shows a simple comparison of the
profiles where ion signals for the eight species
were normalized to the wt-SAP signal, seven
data points for each individual with the eighth
serving to normalize between individuals.
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Fig 2. MSIA analyses for (A) C-reactive protein (CRP), (B) retinol binding protein (RBP), (C) serum amyloid
P component (SAP), and (D) a MALDI-TOF MS analysis of the stock plasma (diluted 100-fold with water).
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Signal for each species can be evaluated on its
own, or as part of the collective profile, and
put into perspective with regard to the origin
of the protein species and the medical history
of the individual. For instance, three individu-
als, Nos. 4, 6, and 8, exhibited exceedingly high
levels of CRP. The histories of these individu-
als revealed that subject No. 4 was 48 h post-
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Fig. 3. Multi-analyte MSIA. Eight species (as identified) were selectively extracted from plasma using a single
MSIA-Tip derivatized with polyclonal antibodies towards RBP, CRP, and SAP.
Fig. 4. Four (of eight) profiles used in validating CRP response vs concentration. CRP response is observed to
increase (inset) proportional to amount of purified CRP standard added to the stock plasma sample.
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surgery when the plasma sample was col-
lected, whereas subject No. 6 suffered from
chronic rheumatoid arthritis and No. 8 had
recently suffered an acute myocardial infarc-
tion. The elevated levels of CRP in these indi-
viduals is in agreement with the fact that CRP
is an established acute-phase protein known
to respond to both immediate and chronic
inflammation (24), as well as a marker of car-
diovascular health (25). Although not previ-
ously cataloged as an endogenous species,
the truncated CRP variant mimics the CRP
response in these individuals, which may be
expected considering that the two species are
linked biologically. Individual No. 7 was
noted to have elevated levels of all the signals
in the profile, with the exception of the wt-
SAP (normalization) signal. This observation
was consistent with the individual having a
below average level of the fully glycosylated
SAP, the cause of which remains unclear. 
Conclusion
The need for targeted mass spectrometric
analysis of human proteins increases dramati-
cally as the field of clinical proteomics evolves
from the discovery phase to validation and
application. Given here has been the develop-
ment and use of a proteomics approach for
the expression profiling a select group of pro-
teins from human plasma. Importantly, the
approach is able to yield information towards
a specific question. The RBP–CRP–SAP MSIA
was designed to recognize, and if chosen
rigorously quantify, changes in the plasma
concentration of CRP. Notwithstanding this
ability, the profiling approach also contains an
element of discovery. As a result of genetic
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Fig. 5. Response curve generated from the CRP standard addition series. A linear response (r 2 = 0.984) is
observed for CRP signal intensity (normalized to wt-SAP signal) vs concentration of CRP(added) standard. Error
bars for each point indicated the standard error determined from five 100-laser shot mass spectra.
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polymorphism, splice variants, and posttrans-
lational modifications, any particular protein
has the potential of being produced as one
of numerous different variants. Moreover,
additional variants can be created by the
natural metabolism/catabolism of the protein
after expression. As a case in-point, the three
proteins under investigation, RBP–CRP–SAP,
actually register as eight identifiable and con-
sistently observed species in the expression
profiling. The ability to readily monitor such
variants clearly adds an additional dimension
of performance to an otherwise routine anal-
ysis, which in turn allows subtle changes in
protein structure to be discovered and investi-
gated. Given these abilities and their general
application in number, MSIA is viewed as an
exceptional approach for the expression profil-
ing of select protein targets in human plasma to
determine qualitative and quantitative changes
between individuals. Such selected expression
profiling stands to find use in population
screening and validation efforts subsequently
derived from discoveries made through ongo-
ing comparative proteomics studies.
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